Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 161 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Injections, Intravenous Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)

NCT01780233
View directory record Official record
Conditions
Pain
Interventions
Fentanyl 400 µg sublingual spray, Actiq® 400 µg transmucosally, Fentanyl citrate injection 100 µg intravenously, Naltrexone 50 mg
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Not applicable Interventional

An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

NCT00002021
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting

NCT04592198
View directory record Official record
Conditions
Nausea With Vomiting Chemotherapy-Induced
Interventions
Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
Drug
Lead sponsor
Xiamen LP Pharmaceutical Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Anaheim, California • Ocala, Florida • Skokie, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

NCT03279302
View directory record Official record
Conditions
Healthy Subjects
Interventions
Glepaglutide
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Phase 4 Interventional Results available

A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

NCT00503113
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva], Alendronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
60 Years and older · Female only
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Riverside, California • Lakewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 22, 2026, 11:59 AM EDT
Not listed Phase 2 Interventional

Chemotherapy in Treating Patients With Metastatic Kidney Cancer

NCT00024388
View directory record Official record
Conditions
Kidney Cancer
Interventions
DHA-paclitaxel
Drug
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Tucson, Arizona • Los Angeles, California • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2008 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of KINE-101 in Healthy Volunteers

NCT07343323
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KINE-101, Placebo
Drug
Lead sponsor
Kine Sciences Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 22, 2026, 11:59 AM EDT
Terminated Phase 1 Interventional

RTA 744 Injection in Patients With Leptomeningeal Disease

NCT00512460
View directory record Official record
Conditions
Neoplastic Meningitis, Solid Tumor, Lymphoma, Leukemia, Brain Tumor
Interventions
RTA 744
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Phase 1 Interventional

Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors

NCT00355888
View directory record Official record
Conditions
Cancer
Interventions
MBP-426
Drug
Lead sponsor
Mebiopharm Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Not applicable Interventional

Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy

NCT00000722
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 22, 2026, 11:59 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion

NCT00924963
View directory record Official record
Conditions
Pain
Interventions
J-Tip jet injector, Jet injection saline, lidocaine cream
Device · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Liberty Township, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Phase 1 Interventional

A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea

NCT00000980
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Spiramycin
Drug
Lead sponsor
Rhone-Poulenc Rorer
Industry
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Diego, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)

NCT06842121
View directory record Official record
Conditions
Parenteral Nutrition
Interventions
Sodium Glycerophosphate Injection, Sodium Phosphates Injection
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 22, 2026, 11:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlates and Consequences of Increased Immune Activation in Injection Drug Users

NCT01831284
View directory record Official record
Conditions
Intravenous Drug Usage
Interventions
Sigmoidoscopy with biopsy
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 55 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 22, 2026, 11:59 AM EDT
Not listed Phase 2 Interventional

Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis

NCT04448106
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis Shoulder
Interventions
Celltex- AdMSCs
Biological
Lead sponsor
Celltex Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Ramucirumab (LY3009806) in Healthy Participants

NCT04495478
View directory record Official record
Conditions
Healthy
Interventions
Ramucirumab - IV, Placebo - IV, Ramucirumab - SC, Placebo - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 22, 2026, 11:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

NCT07599670
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABBV-1758, Placebo for ABBV-1758
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Irvine, California • Boulder, Colorado • Bradenton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 11:59 AM EDT
Recruiting Phase 1 Interventional

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion and Intra-Articular Injection for RA

NCT05003934
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
Biological
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 11:59 AM EDT
Terminated Phase 1 Interventional Results available

An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

NCT03029988
View directory record Official record
Conditions
Liver Metastases, Colorectal Carcinoma
Interventions
Tilmanocept (Technetium Tc 99m tilmanocept Injection), SPECT/CT Imaging
Drug · Procedure
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 22, 2026, 11:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

NCT07751042
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
STX-003, KEYTRUDA®
Biological
Lead sponsor
Strand Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 11:59 AM EDT
Terminated Phase 4 Interventional Results available

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

NCT03119662
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Visipaque, Placebos
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Change the Cycle: An RCT to Prevent Injection Initiation

NCT02774954
View directory record Official record
Conditions
Substance Abuse, Intravenous, HIV, Heroin Dependence, Opioid Dependence, Cocaine Dependence, Amphetamine Dependence
Interventions
Change the Cycle
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
979 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 22, 2026, 11:59 AM EDT
Completed Not applicable Interventional

A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

NCT00002292
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
LyphoMed
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rosemont, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 11:59 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

NCT02013336
View directory record Official record
Conditions
Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
Interventions
MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
12 Months to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
5
States / cities
Cincinnati, Ohio • Oklahoma City, Oklahoma • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 11:59 AM EDT